A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia

Last updated: June 25, 2024
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Overall Status: Completed

Phase

1

Condition

Tourette's Syndrome

Schizotypal Personality Disorder (Spd)

Psychosis

Treatment

Placebo

SEP-363856

Clinical Study ID

NCT05848700
SEP361-121
  • Ages 18-65
  • All Genders

Study Summary

A Clinical Study to learn if SEP-363856 has physical dependence in adults with schizophrenia. This study will be held in approximately 6 study sites in the United States. It will be accepting male and female participants age 18 years to 65 years. Participation will be up to approximately10 weeks.

Eligibility Criteria

Inclusion

Inclusion Criteria: (this list is not all inclusive)

  • Male or female subject between 18 and 65 years of age (inclusive) at the time ofinformed consent.

  • Subject meets Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteriafor a primary diagnosis of schizophrenia as established by clinical interview (usingthe DSM-5 as a reference and confirmed using the Structured Clinical Interview forDSM-5, Clinical Trials Version [SCID-CT]).

  • Subject must have a Clinical Global Impression-Severity Scale (CGI-S) score ≤ 4 (normal to moderately ill) at Screening and Day 1.

  • Subject must have a PANSS total score ≤ 80 at Screening and a score of ≤ 4 on thefollowing PANSS items at Screening: P7 (hostility) and G8 (uncooperativeness).

  • Subject has been taking an antipsychotic for at least 6 weeks prior to Screening andhas had no change in antipsychotic medication(s) (minor dose adjustments fortolerability purposes may be permitted) for at least 6 weeks prior to Screening.

Exclusion

Exclusion Criteria: (this list is not all inclusive)

  • Subject has a DSM-5 diagnosis or presence of symptoms consistent with a currentDSM-5 diagnosis other than schizophrenia.

  • Subject has attempted suicide within 6 months prior to Screening.

  • Subject answers "yes" to "Suicidal Ideation" Item 4 (active suicidal ideation withsome intent to act, without specific plan) or Item 5 (active suicidal ideation withspecific plan and intent) on the Columbia Suicide Severity Rating Scale (C-SSRS) atScreening (ie, in the past 1 month) or at any subsequent C-SSRS assessment prior todosing (ie, since last visit).

  • Subject is at significant risk of harming him/herself or others (passive or active)according to the Investigator's judgment.

Study Design

Total Participants: 60
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 1
Study Start date:
June 21, 2023
Estimated Completion Date:
March 15, 2024

Study Description

This is a double-blind, placebo-controlled, randomized withdrawal study comparing abrupt discontinuation of SEP-363856 (SEP-363856 switched to placebo) to continuous SEP-363856 treatment in male and female adult subjects with schizophrenia.

Connect with a study center

  • Woodland International Research Group, LLC

    Little Rock, Arkansas 72211
    United States

    Site Not Available

  • Woodland Research Northwest

    Rogers, Arkansas 72758
    United States

    Site Not Available

  • Segal Trials, Larkin Behavioral Health Services - Inpatient & Early Phase Research Site

    Hollywood, Florida 33021
    United States

    Site Not Available

  • Behavioral Clinical Research, Inc

    Miami Lakes, Florida 33016
    United States

    Site Not Available

  • Research Centers of America at Fort Lauderdale Behavioral Health Center

    Oakland Park, Florida 33334
    United States

    Site Not Available

  • Atlanta Center for Medical Research

    Atlanta, Georgia 30331
    United States

    Site Not Available

  • Neuro-Behavioral Clinical Research, Inc

    North Canton, Ohio 44720
    United States

    Site Not Available

  • Pillar Clinical Research, LLC

    Richardson, Texas 75080
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.